We are live on ! Find out more
SM

SB Management Portfolio holdings

AUM $516M
1-Year Est. Return 40.71%
This Fund
S&P 500
This Quarter Est. Return
+8.63%
1 Year Est. Return
-40.71%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$8.5B
AUM Growth
-$7.02B
Cap. Flow
-$7.74B
Cap. Flow %
-91.01%
Top 10 Hldgs %
94.15%
Holding
49
New
17
Increased
5
Reduced
4
Closed
16

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$57.4M
2
ABCL icon
AbCellera Biologics
ABCL
+$55.2M
3
IS
ironSource Ltd.
IS
+$53.8M
4
IPSC icon
Century Therapeutics
IPSC
+$50.7M
5
EOCW.U
Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
EOCW.U
+$49.6M

Top Sells

Rank Stock Value
1
META icon
Meta Platforms (Facebook)
META
+$3.18B
2
AMZN icon
Amazon
AMZN
+$1.21B
3
MSFT icon
Microsoft
MSFT
+$1.03B
4
PYPL icon
PayPal
PYPL
+$647M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$575M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 66.47%
2 Healthcare 10.7%
3 Financials 10.69%
4 Technology 10.16%
5 Communication Services 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMZN icon
1
Amazon
AMZN
$2.66T
$5.65B 66.47%
32,868,520
-7,279,120
-18% -$1.21B
TSM icon
2
TSMC
TSM
$2.07T
$812M 9.54%
6,754,120
-4,409,742
-40% -$517M
PYPL icon
3
PayPal
PYPL
$49.9B
$702M 8.26%
2,409,413
-2,450,000
-50% -$647M
PACB icon
4
Pacific Biosciences
PACB
$447M
$345M 4.05%
9,861,089
– –
ABCL icon
5
AbCellera Biologics
ABCL
$1.97B
$216M 2.54%
9,817,190
+2,000,000
+26% +$55.2M
WGS icon
6
GeneDx Holdings
WGS
$1.88B
$59.3M 0.7%
128,173
+25,758
+25% +$11.1M
IPSC icon
7
Century Therapeutics
IPSC
$406M
$58.7M 0.69%
+2,000,000
New +$50.7M
LYEL icon
8
Lyell Immunopharma
LYEL
$326M
$56.8M 0.67%
+175,000
New +$57.4M
IS
9
DELISTED
ironSource Ltd.
IS
$52.5M 0.62%
+5,000,000
New +$53.8M
SANA icon
10
Sana Biotechnology
SANA
$877M
$51.6M 0.61%
2,625,153
– –
ADPT icon
11
Adaptive Biotechnologies
ADPT
$3.67B
$50.7M 0.6%
+1,240,000
New +$48.2M
EOCW.U
12
DELISTED
Elliott Opportunity II Corp. Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
EOCW.U
$49.5M 0.58%
+4,950,000
New +$49.6M
HERA
13
DELISTED
FTAC Hera Acquisition Corp. Class A Ordinary Shares
HERA
$48.8M 0.57%
+5,000,000
New +$48.9M
EQRX
14
DELISTED
EQRx, Inc. Common Stock
EQRX
$41.3M 0.49%
+4,000,000
New +$41M
KVSC
15
DELISTED
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
$39.5M 0.46%
4,000,000
+500,000
+14% +$5.02M
CPUH
16
DELISTED
Compute Health Acquisition Corp.
CPUH
$39.3M 0.46%
+4,000,000
New +$39.3M
NXDR
17
Nextdoor Holdings
NXDR
$912M
$34.8M 0.41%
3,500,000
+500,000
+17% +$5.05M
LENZ
18
LENZ Therapeutics
LENZ
$162M
$30.5M 0.36%
+141,915
New +$24.7M
REVH
19
DELISTED
Revolution Healthcare Acquisition Corp. SAIL Class A Common Stock
REVH
$29.5M 0.35%
+3,000,000
New +$29.6M
AURCU
20
DELISTED
Aurora Acquisition Corp. Unit
AURCU
$28.1M 0.33%
2,700,000
– –
SVFAU
21
DELISTED
SVF Investment Corp. Unit
SVFAU
$22.4M 0.26%
2,200,000
– –
SYM icon
22
Symbotic
SYM
$5.25B
$19.9M 0.23%
2,000,000
– –
FTAA
23
DELISTED
FTAC Athena Acquisition Corp. Class A Ordinary Share
FTAA
$19.7M 0.23%
+2,000,000
New +$19.7M
KVSA
24
DELISTED
Khosla Ventures Acquisition Co. Class A Common Stock
KVSA
$14.8M 0.17%
1,500,000
+500,000
+50% +$5.08M
SVFB
25
DELISTED
SVF Investment Corp. 2 Class A Ordinary Shares
SVFB
$9.95M 0.12%
1,000,000
– –
1
2

Similar funds

GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
HT
Hefren-Tillotson Pittsburgh, Pennsylvania $523M AUM 4.13% 1-Year Est. Return
HAM
HHR Asset Management Berkeley Heights, New Jersey $552M AUM 15.61% 1-Year Est. Return
FC
Ferris Capital Marlborough, Massachusetts $437M AUM 8.6% 1-Year Est. Return
FC
Full18 Capital Westport, Connecticut $434M AUM 5.79% 1-Year Est. Return
VR
Viridian RIA Bothell, Washington $430M AUM 6.31% 1-Year Est. Return
MCM
Model Capital Management Wellesley, Massachusetts $422M AUM 2.75% 1-Year Est. Return
TM
THRC Management Cisco, Texas $634M AUM

SB Management's Q2 2021 Portfolio in Review

As of Q2 2021, SB Management held 49 positions worth $8.5B, down 45% from $15.5B the previous quarter. Its ten largest holdings account for 94% of the portfolio.

SB Management withdrew a net $7.74B in Q2 2021, closing 16 positions and reducing 4 holdings. Its most notable exit was Meta Platforms (Facebook), an estimated $3.18B position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 66% of assets, up from 40% a quarter earlier, followed by Healthcare and Financials.

Against the trend, SB Management opened a new position in Lyell Immunopharma worth $56.8M.

  • SB Management's largest Q2 2021 buy was Lyell Immunopharma: 175,000 shares worth $56.8M.
  • SB Management added most to AbCellera Biologics in Q2 2021, an estimated $55.2M increase.
  • SB Management's biggest Q2 2021 reduction was Amazon, cutting an estimated $1.21B.
  • SB Management fully exited Meta Platforms (Facebook) in Q2 2021, selling an estimated $3.18B.
  • SB Management's ten largest holdings make up 94% of its $8.5B portfolio in Q2 2021.
  • SB Management opened 17 new positions and closed 16 in Q2 2021.
  • SB Management's portfolio value fell 45% quarter-over-quarter to $8.5B.

Based on SB Management's 13F filing for Q2 2021, filed 16 Aug 2021.